Amylyx Pharmaceuticals (AMLX) Revenue (2021 - 2024)

Amylyx Pharmaceuticals' Revenue history runs 4 years deep, the most recent figure standing at -$665000.0 for Q4 2024.

• In Q4 2024, Revenue fell 100.88% year-over-year to -$665000.0; the TTM figure through Sep 2025 stood at -$665000.0 (down 100.4% YoY), while the FY2024 annual figure was $87.4 million, down 77.06% from the prior year.
• Revenue was -$665000.0 for Q4 2024 at Amylyx Pharmaceuticals, down from $416000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $108.4 million in Q2 2023 to a low of -$665000.0 in Q4 2024.
• Historically, Revenue has averaged $44.0 million across 4 years, with a median of $21.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Revenue jumped 18673.86% in 2023, then slumped 100.88% in 2024.
• A 4-year view of Revenue shows it stood at $285000.0 in 2021, then surged by 7508.07% to $21.7 million in 2022, then surged by 250.34% to $76.0 million in 2023, then sank by 100.88% to -$665000.0 in 2024.
• The last three Revenue figures came in at -$665000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024), per Business Quant data.